MGD019 DART(R) Protein in Unresectable/Metastatic Cancer

Study Overview

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of MGD019.

Study Description

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART(R) Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms

  • ClinicalTrials.gov Identifier: NCT03761017
  • Protocol Number: 19-090

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000